Literature DB >> 24092554

2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.

Sarah Ringold1, Pamela F Weiss, Timothy Beukelman, Esi Morgan DeWitt, Norman T Ilowite, Yukiko Kimura, Ronald M Laxer, Daniel J Lovell, Peter A Nigrovic, Angela Byun Robinson, Richard K Vehe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24092554      PMCID： PMC5408575          DOI： 10.1002/art.38092

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  73 in total

Review 1.  The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis.

Authors:  Joost Frans Swart; Daantje Barug; Michelle Möhlmann; Nico M Wulffraat
Journal:  Expert Opin Biol Ther       Date:  2010-10-28       Impact factor: 4.388

2.  Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders.

Authors:  S Sawhney; P Woo; K J Murray
Journal:  Arch Dis Child       Date:  2001-11       Impact factor: 3.791

3.  Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine.

Authors:  A Ravelli; F De Benedetti; S Viola; A Martini
Journal:  J Pediatr       Date:  1996-02       Impact factor: 4.406

4.  Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis.

Authors:  Yukiko Kimura; Paulo Pinho; Gary Walco; Gloria Higgins; Donna Hummell; Ilona Szer; Michael Henrickson; Sandra Watcher; Andreas Reiff
Journal:  J Rheumatol       Date:  2005-05       Impact factor: 4.666

5.  Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.

Authors:  P Woo; T R Southwood; A M Prieur; C J Doré; J Grainger; J David; C Ryder; N Hasson; A Hall; I Lemelle
Journal:  Arthritis Rheum       Date:  2000-08

Review 6.  Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases.

Authors:  R Mouy; J L Stephan; P Pillet; E Haddad; P Hubert; A M Prieur
Journal:  J Pediatr       Date:  1996-11       Impact factor: 4.406

7.  Macrophage activation syndrome in a child with systemic juvenile rheumatoid arthritis.

Authors:  Mina Hur; Young Chul Kim; Kyu Man Lee; Kwang Nam Kim
Journal:  J Korean Med Sci       Date:  2005-08       Impact factor: 2.153

8.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

Authors:  Nicolino Ruperto; Daniel J Lovell; Pierre Quartier; Eliana Paz; Nadina Rubio-Pérez; Clovis A Silva; Carlos Abud-Mendoza; Ruben Burgos-Vargas; Valeria Gerloni; Jose A Melo-Gomes; Claudia Saad-Magalhães; Flavio Sztajnbok; Claudia Goldenstein-Schainberg; Morton Scheinberg; Immaculada Calvo Penades; Michael Fischbach; Javier Orozco; Philip J Hashkes; Christine Hom; Lawrence Jung; Loredana Lepore; Sheila Oliveira; Carol A Wallace; Leonard H Sigal; Alan J Block; Allison Covucci; Alberto Martini; Edward H Giannini
Journal:  Lancet       Date:  2008-07-14       Impact factor: 79.321

9.  Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement.

Authors:  Patricia Woo; Nicholas Wilkinson; Anne-Marie Prieur; Taunton Southwood; Valentina Leone; Polly Livermore; Helena Wythe; David Thomson; Tadamitsu Kishimoto
Journal:  Arthritis Res Ther       Date:  2005-09-15       Impact factor: 5.156

10.  Rapid and sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in a patient with nephrotic syndrome secondary to systemic juvenile idiopathic arthritis-related amyloidosis.

Authors:  Miguel De La Torre; Luis Arboleya; Sergio Pozo; Jesús Pinto; Julio Velasco
Journal:  NDT Plus       Date:  2011-03-02
View more
  80 in total

1.  Successful treatment of macrophage activation syndrome due to systemic onset juvenile idiopathic arthritis with antithymocyte globulin.

Authors:  Kubra Ozturk; Zelal Ekinci
Journal:  Rheumatol Int       Date:  2015-07-26       Impact factor: 2.631

Review 2.  Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials.

Authors:  Simon Tarp; Gil Amarilyo; Ivan Foeldvari; Robin Christensen; Jennifer M P Woo; Neta Cohen; Tracy D Pope; Daniel E Furst
Journal:  Rheumatology (Oxford)       Date:  2015-11-30       Impact factor: 7.580

3.  Spectral-domain optical coherence tomography findings of the macula in 500 consecutive patients with uveitis.

Authors:  R S Grajewski; A C Boelke; W Adler; S Meyer; A Caramoy; B Kirchhof; C Cursiefen; L M Heindl
Journal:  Eye (Lond)       Date:  2016-07-08       Impact factor: 3.775

4.  A Bullseye for Children With Systemic Juvenile Idiopathic Arthritis.

Authors:  Lauren A Henderson
Journal:  Arthritis Rheumatol       Date:  2019-05-27       Impact factor: 10.995

Review 5.  Management of juvenile idiopathic arthritis: hitting the target.

Authors:  Claas Hinze; Faekah Gohar; Dirk Foell
Journal:  Nat Rev Rheumatol       Date:  2015-01-06       Impact factor: 20.543

6.  Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis.

Authors:  Hatice Ezgi Baris; Edwin Anderson; Betul Sozeri; Fatma Dedeoglu
Journal:  Clin Rheumatol       Date:  2018-09-20       Impact factor: 2.980

Review 7.  Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?

Authors:  Heinrike Schmeling; Gerd Horneff; Susanne M Benseler; Marvin J Fritzler
Journal:  Nat Rev Rheumatol       Date:  2014-08-12       Impact factor: 20.543

8.  2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis.

Authors:  Sarah Ringold; Sheila T Angeles-Han; Timothy Beukelman; Daniel Lovell; Carlos A Cuello; Mara L Becker; Robert A Colbert; Brian M Feldman; Polly J Ferguson; Harry Gewanter; Jaime Guzman; Jennifer Horonjeff; Peter A Nigrovic; Michael J Ombrello; Murray H Passo; Matthew L Stoll; C Egla Rabinovich; Rayfel Schneider; Olha Halyabar; Kimberly Hays; Amit Aakash Shah; Nancy Sullivan; Ann Marie Szymanski; Marat Turgunbaev; Amy Turner; James Reston
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-04-25       Impact factor: 4.794

Review 9.  Biologics in juvenile idiopathic arthritis: a narrative review.

Authors:  Federica Vanoni; Francesca Minoia; Clara Malattia
Journal:  Eur J Pediatr       Date:  2017-07-20       Impact factor: 3.183

10.  Low pretreatment levels of myeloid-related protein-8/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis.

Authors:  Mikel Alberdi-Saugstrup; Susan Nielsen; Pernille Mathiessen; Claus Henrik Nielsen; Klaus Müller
Journal:  Clin Rheumatol       Date:  2016-08-25       Impact factor: 2.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.